Novartis Reports Results from the P-IIIb (V-INITIATE) Study of Leqvio for Treating Atherosclerotic Cardiovascular Disease (ASCVD)
Shots:
- The 12mos. P-IIIb (V-INITIATE) study assesses the efficacy of earlier Leqvio addition vs usual care in ASCVD patients (n= 450) with LDL-C ≥70 mg/dL in spite of receiving maximally tolerated statin therapy across the US
- The study demonstrated LDL-C reductions in 60% vs 7% of patients (73% of them consisted statin therapy alone), LDL-C <70 mg/dL was observed in 81.8% vs 22.2% of them and 5.8% vs 16.7% of them maintained adherence to lipid-lowering therapy with similar rates of statin discontinuation
- The safety profile was consistent with the previous P-III (ORION-3 and ORION-8) trials showing sustained safety for up to 6yrs.
Ref: Novartis | Image: Novartis
Related Post:- Novartis Leqvio (inclisiran) Receives the US FDA’s Approval for the Treatment of Atherosclerotic Cardiovascular Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
